Compare GDEN & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDEN | VALN |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.2M | 820.0M |
| IPO Year | 1999 | 2021 |
| Metric | GDEN | VALN |
|---|---|---|
| Price | $27.28 | $9.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $32.25 | $15.75 |
| AVG Volume (30 Days) | ★ 229.2K | 24.9K |
| Earning Date | 02-26-2026 | 11-20-2025 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $643,485,000.00 | $211,089,992.00 |
| Revenue This Year | N/A | $3.64 |
| Revenue Next Year | $1.89 | $12.23 |
| P/E Ratio | $132.65 | ★ N/A |
| Revenue Growth | N/A | ★ 13.48 |
| 52 Week Low | $19.57 | $4.20 |
| 52 Week High | $35.49 | $12.25 |
| Indicator | GDEN | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 63.27 |
| Support Level | $26.85 | $8.77 |
| Resistance Level | $27.72 | $10.03 |
| Average True Range (ATR) | 0.45 | 0.36 |
| MACD | -0.06 | 0.18 |
| Stochastic Oscillator | 48.18 | 86.07 |
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.